Product Pipeline
Asubio has an active portfolio of investigational compounds in development in the United States. Following is an overview of new drug candidates, their target indications and phase of clinical development.
| Entity | Phase of Development |
Indication | Status |
Carperitide |
III | AMI | Available for Licensing |
Piclozotan |
II | Motor Complications Parkinson’s Disease |
Available for Licensing |
Piclozotan |
II | Stroke | Available for Licensing |
SUN11031 |
II | Cachexia | Clinical Development |
SUN13834 |
II | Atopic Dermatitis | Clinical Development |
--- |
Pre-IND | CNS/CV Disorders | Planning |
Carperitide - SUN4936
Carperitide is a recombinant form of human atrial natriuretic peptide (hANP) that is currently available for licensing. While the major pharmacological effects of natriuretic peptides are known to be vasorelaxation and natriuresis, emerging evidence suggests that carperitide, when administered at doses that are considered sub-hemodynamic, may have a direct protective effect on cardiomyocytes under conditions consistent with ischemia/reperfusion - related injury in acute myocardial infarction (AMI).
Ischemic heart disease is one of the main causes of chronic heart failure, a major cause of morbidity and mortality worldwide. There are more than 850,000 new or recurrent AMIs each year in the U.S. alone. Ischemia/reperfusion-related sequelae occurring by discharge play a significant role in the long-term morbidity and mortality associated with AMI. Few medications, however, have been shown to decrease ischemia or reperfusion injury. Recent clinical studies have provided evidence that carperitide administration can significantly reduce myocardial damage after AMI. Scientific data supports further development of carperitide as adjunct therapy to PCI in the acute treatment of myocardial infarction.
Back to Top
Piclozotan - SUN N4057
As many as 6 million people worldwide suffer from PD including 1 million in the US alone, making it the 2nd most prevalent
neuro-degenerative disease. The symptoms of PD may include tremor, slowness of movement, stiffness and rigidity of limbs and balance problems.
L-Dopa remains the gold standard therapy in the treatment of the symptoms of PD. While the beneficial effects of L-Dopa treatment are
maintained throughout the entire course of the disease, chronic L-Dopa treatment is associated with the development of adverse events called
motor complications (defined as motor fluctuations/increased OFF time and dyskinesia) in most patients over time. Currently, no treatment
exists that can adequately treat one element of L-dopa-induced motor complications (dyskinesia or OFF Time) without potentially exacerbating
the other. Pharmacologic advances that control both OFF Time and dyskinesia would be of real benefit to PD patients as it would allow PD
patients to optimize their L-Dopa dose chronically to meet original treatment goals.
Piclozotan is an investigational serotonin (5HT1A) receptor agonist devoid of DA antagonist activity in early phase clinical development for the
treatment of motor complications in Parkinson's disease at Asubio Pharmaceuticals Inc. It has also been investigated for the treatment of
acute ischemic stroke. 5-HT neurons may be a key source of unregulated DA concentrations in the brain, which are thought to be the cause of
motor complications in PD. Clinical and non-clinical findings suggest that co-administering Piclozotan with L-dopa inhibits excessive 5-HT
neuronal activity and may effectively treat both dyskinesia and OFF time associated with L-dopa use in patients with PD. Piclozotan is available
for licensing worldwide. For further information, please click here.
Back to Top
SUN11031
SUN11031 is a peptide hormone currently under Phase II investigation for the treatment of cachexia. Cachexia is the accelerated loss of tissue, primarily skeletal muscle, in the context of a chronic inflammatory response to many chronic or end-stage diseases. Clinically cachexia is characterized by weakness and a noticeable and progressive loss of body weight, fat, and muscle, and is a condition distinct from starvation. The largest cachexia patient populations are found in patients with COPD, chronic heart failure (CHF) and cancer. Similar changes have also been observed in the elderly. In COPD, CHF and cancer, 15% or more of patients suffer from cachexia associated with their condition. These patients experience both increased morbidity and mortality due to their cachexia, and unfortunately, few treatment options exist that both increase muscle mass and improve functional performance. SUN11031 has multiple activities that are expected to be beneficial in the treatment of cachexia.
Back to Top
SUN13834
SUN13834 is a chymase inhibitor currently under Phase II investigation for the treatment of atopic dermatitis (AD), commonly known as eczema. AD is a chronic inflammatory disease of the skin characterized by dry, red, extremely itchy areas of inflammation, most commonly on the face, inside the elbows, behind the knees, and on the hands and feet, that may cover over 20 to 30% of the body. AD is a very common disease in
children with prevalence estimates ranging from 10 to 20%. Approximately 20 million Americans have symptoms of AD. Although AD may occur at any
age, it most often begins in infancy and childhood.
Chymase is a chymotrypsin-like serine protease exclusively stored in secretory granules of mast cells and is thought to participate in
allergic inflammatory diseases. Preclinical models have suggested that inhibition of chymase with SUN13834 may reduce the inflammation and
pruritus associated with atopic dermatitis.
Back to Top